Understanding how a tiny molecule affects lupus and kidney problems
Official title: miR-21 regulation of autoreactive B cell and lupus nephritis development
Funded at Thomas Jefferson University · NIH-11139640 · Data updated 2026-11-12
This research explores how a small molecule called miR-21 contributes to lupus and its effects on the kidneys.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 18, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $533,851 |
| NIH project number | 5R01AI155666-04 |
| Project ID | NIH-11139640 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with systemic lupus erythematosus (SLE), especially those with kidney involvement (lupus nephritis), could potentially benefit from future treatments developed from this research.
✕Less likely to help
Patients without systemic lupus erythematosus or related autoimmune conditions may not directly benefit from this specific research.
What this research studies
Our bodies have tiny molecules called microRNAs, and one called miR-21 seems to be more active in people with lupus. This project aims to understand how miR-21 encourages the immune system to produce harmful antibodies that attack the body's own tissues. We are particularly interested in how this process leads to lupus and kidney problems. By uncovering these details, we hope to find new ways to help control the disease. This work could lead to new treatments for lupus.
Why it matters
Potential benefit: If successful, this work could lead to the discovery of new targeted therapies for systemic lupus erythematosus (SLE), a debilitating disease.
How similar studies have gone: Previous findings in mouse models have shown a role for miR-21 in autoimmune diseases, but the exact mechanisms in lupus are still being identified.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Rahman, Ziaur — Thomas Jefferson University
- Study coordinator: Rahman, Ziaur
Related research
Other NIH-funded projects on the same topics.
-
Glycoprotein urine markers that signal lupus nephritis treatment response
A novel test uses urine glycoprotein patterns to show how well lupus nephritis is responding to standard treatment.
-
PTPRS and lupus nephritis: a new target to reduce kidney damage in lupus
Aims to understand how PTPRS contributes to kidney inflammation and scarring in lupus nephritis and explore targeting it to help patients.
-
Sodium’s effect on kidney B cells in lupus kidney disease
This grant explores how high sodium in the kidneys affects B cells in lupus nephritis and whether blocking a key cellular pump could reduce kidney damage.
-
Oral CD11b Activator for Lupus Nephritis
A new oral CD11b activating drug is being explored to help people with lupus nephritis by targeting immune pathways that cause kidney inflammation.
-
Objective classification of lupus nephritis using computer vision
A new computer vision tool uses deep learning to classify lupus nephritis from kidney tissue images to help doctors predict outcomes for patients with lupus.
-
AI-powered look at lupus nephritis in humans and mice
Researchers will use artificial intelligence to compare kidney tissue from people with lupus nephritis to tissue from mouse models, aiming to understand why treatments work differently in humans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.